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Antibiotic allergies are frequently reported and have significant impacts upon appropriate prescribing 
and clinical outcomes. We surveyed infectious diseases physicians, allergists, clinical immunologists 
and hospital pharmacists to evaluate antibiotic allergy knowledge and service delivery in Australia and 
New Zealand. 
Methods 
An online multi-choice questionnaire was developed and endorsed by representatives of the 
Australasian Society of Clinical Immunology and Allergy (ASCIA), Australasian Society of Infectious 
Diseases (ASID) and Society of Hospital Pharmacists Australia (SHPA). The 37-item survey was 
distributed in April 2015 to members of ASCIA, ASID, SHPA and Royal Australasian College of 
Physicians. 
Results 
Of 277 respondents, 94% currently use or would utilise antibiotic allergy testing (AAT) and reported 
seeing up to 10 patients/week labelled as antibiotic-allergic. Forty-two per cent were not aware of or 
did not have AAT available. Most felt that AAT would aid antibiotic selection, antibiotic 
appropriateness and antimicrobial stewardship (79%, 69% and 61%, respectively). Patients with 
histories of immediate hypersensitivity were more likely to be referred than those with delayed 
hypersensitivities (76% vs. 41%, p=0.0001). Lack of specialist physicians (20%) and personal 
experience (17%) were barriers to service delivery. A multidisciplinary approach was the preferred 
AAT model (53%). Knowledge gaps were identified, with the majority over-estimating rates of 
penicillin/cephalosporin (78%), penicillin/carbapenem (57%) and penicillin/monobactam (39%) cross-
reactivity.  
Conclusions 
A high burden of antibiotic allergy labelling and demand for AAT is complicated by a relative lack 
availability or awareness of AAT services in Australia and New Zealand. Antibiotic allergy education 
and deployment of AAT, accessible to community and hospital-based clinicians, may improve clinical 
decisions and reduce antibiotic allergy impacts. A collaborative approach involving ID physicians, 
pharmacists and allergists/immunologists is required. 
KEYWORDS:  
Antibiotic allergy, adverse drug reactions, antibiotic allergy testing, antimicrobial stewardship, skin 
testing 
 












Despite 10% of the population reporting a penicillin “allergy”, less than 1% of the population are 
confirmed as being truly penicillin allergic by formal testing1-5. In Australia, the prevalence of 
antimicrobial allergy labels in hospitalised inpatients is 18% and higher in populations with more 
frequent antibiotic use (e.g. immunocompromised hosts)6, 7. Antimicrobial allergy labels are 
associated with broad spectrum antibiotic usage, antimicrobial resistance, inappropriate prescribing, 
morbidity and mortality 4, 7, 8. The majority of antibiotic allergy labels reflect either pharmacologically 
predictable side effects or mild non-immunologically mediated drug reactions that are amendable to 
rechallenge or symptomatic management as necessary9, 10. Antibiotic allergy testing (AAT), which 
combines skin prick testing (SPT), intradermal testing (IDT) and ingestion (usually oral) challenge, 
has a high negative-predictive value and can therefore accurately de-label patients previously 
suspected to have an allergy on clinical criteria alone 1, 11, 12. In an era of increasing antimicrobial 




To identify the need for and potential barriers to development of coordinated multidisciplinary AAT 
programs in Australia & New Zealand we surveyed current knowledge and approaches to antibiotic 
allergy testing among allergists, clinical immunologists, infectious diseases physicians, general 
physicians, and hospital pharmacists.  
METHODS:   
Studied population 
We targeted healthcare providers most closely involved with the diagnosis and management of 
antibiotic allergies and adverse drug reaction reporting in Australian and New Zealand. These 
included allergists/clinical immunologists, infectious diseases physicians, general physicians and 
hospital pharmacists.  
Survey tool 
A 37-item multiple-choice survey was developed to assess the key antibiotic allergy domains: (a) 
prevalence, (b) testing practices (c) benefits to antimicrobial stewardship (AMS), (d) models of care 
and (e) clinician knowledge. Stakeholders represented clinical practice, research and supportive care 
sectors. Consultation and endorsement was sought from the Australasian Society of Clinical 
Immunology and Allergy (ASCIA) and Australasian Society of Infectious Diseases (ASID). Clarity and 
presentation of the survey were evaluated and refined by pre-testing of the questionnaire by two 
infectious diseases physicians, two pharmacists and one allergist/clinical immunologist prior to 
distribution. The survey was delivered electronically via an on-line portal (Survey Monkey, Palo Alto, 











CA, USA) by the ASCIA, ASID, Society of Hospital Pharmacists of Australia (SHPA) and the Royal 
Australasian College of Physicians (RACP). Local ethics approval by the research ethics committee of 
the administering institution (Peter MacCallum Cancer Centre, VIC) was obtained prior to survey 
distribution (Number 15/06L). 
 
Survey distribution 
An invitation and link to the survey was distributed via online modalities only, including RACP weekly 
e-bulletin (n = 13,016), SHPA e-bulletin (n = 2550), ASCIA e-bulletin (n = 320), ASID weekly e-bulletin 
(n = 778) and Ozbug mailing list (n = 800). Ozbug is a moderated and closed mailing list for infectious 
diseases physicians and microbiologists in Australia and New Zealand13. Survey recipients may have 
been members of multiple listed societies or groups. The online survey was open between 15th March 
and 2nd April 2015, and one electronic reminder was sent to each group midway through the survey 
period. Anonymity of respondents and associated healthcare facilities was preserved. 
 
Analysis 
Responses were included if greater than 10% of survey questions were completed by a single 
participant. An overall percentage response rate could not be accurately obtained due to the 
overlapping nature of the surveyed societies and memberships. Survey responses were collated and 
analysed via Stata v13 (Statacorp, College Station Texas). Categorical variables were summarized 
using frequency and percentage and compared between groups using a chi-square test. Continuous 
variables were summarized using mean and standard deviation (SD) or median and inter-quartile 
range as appropriate and compared using a paired t-test or Wilcoxon signed-rank test as appropriate.  
A p-value of <0.05 was deemed statistically significant.  
RESULTS:   
A total of 277 persons completed the survey. Table 1 summarises the baseline demographics of 
respondents. Fifty-eight percent (160/277), were members of the RACP. All Australian states, 
territories and areas of New Zealand were represented in the survey respondents. There were more 
respondents with less than 10 years experience than those with greater than 10 years clinical 
experience (57% [157/277] vs. 43% [120/277], p = 0.002). (Table 1) 
 
(a) Antibiotic allergy label prevalence  
Penicillin allergy label prevalence (8-10% in published literature5, 7) was correctly estimated by 30% 
(83/277) of respondents. The majority of respondents (204/277, 74%) indicated that they reviewed 0-5 











patients per week with a penicillin allergy, with a further 21% (58/277) reviewing 6-10 patients per 
week.  
(b) Allergy testing practices 
Whilst 32% (67/208) indicated they already employed allergy testing, 42% (118/277) of respondents 
were either unaware of or did not have AAT services available to them (Figure 1). Antibiotic allergy 
services were available equally to those with < 10 years or ≥ 10 years clinical experience (p =0.63). 
Varied skin testing practices were available to respondents (Figure 1). The allergy phenotypes 
referred for AAT are demonstrated in Table 2, which shows more respondents refer patients with 
immediate compared with delayed hypersensitivities (76% [110/144] vs. 41% [59/144], p=0.001). 
Gold-standard allergy testing (SPT/IDT plus provocation challenge) was available to 58% (91/156) of 
respondents. Sixty-five percent (157/240) would be comfortable to use penicillin following negative 
gold-standard allergy testing, whilst 35% (83/240) remained unsure or would not employ.  
(c) Benefits of antibiotic allergy testing to antimicrobial stewardship 
When asked if AAT would benefit AMS, 74% (158/213) responded in the affirmative.  The removal of 
an antibiotic allergy label was felt to aid antibiotic selection (78%, 165/212), antibiotic appropriateness 
(69%, 147/212), medication safety (69%, 146/212), AMS services (61%, 129/212) and all of the 
aforementioned (29%, 61/121). Four percent (8/212) of respondents felt there would be no 
measurable benefit to removal of an antibiotic allergy label. A beside point-of-care antibiotic allergy 
tool to assist management of patients with “labels” was thought to be of benefit to 71% (153/214) of 
respondents. 
(d) Antibiotic allergy models of care 
Twenty-six percent (55/209) felt there were no barriers to AAT, whilst 12% (26/209) recorded no 
demand for services.  Barriers to AAT are summarised in Figure 2, with an absence of specialist 
clinicians being the most commonly reported. There was a non-significant trend for those with < 10 
years experience to become new users of AAT services (p=0.08). A referral process involving a 
combined immunology/infectious diseases stream was preferred (47%, 90/192). Alternative 
favourable AAT models included referral to or by the following mechanism: (i) automated referral 
(25%, 47/192), (ii) pharmacist(38%, 72/192), (iii) AMS physician  (45%, 88/192), (iv) allergist (45%, 
86/192), (v) infectious diseases(37%, 71/192). Preferred delivery of AAT was through clinical 
immunology/allergy departments (53%, 112/213), a ‘partnership between infectious diseases, 
pharmacy and immunology’ (39%, 84/213), AMS programs (5%, 10/213) or infectious diseases 
physicians (2.3%, 5/213). More infectious diseases physicians (45%; 35/78) and pharmacists (62%; 
36/58) preferred and saw the benefits of a partnership model than allergists/immunologists (17%; 
9/52) (p=0.001). 
(e) Clinician knowledge regarding antibiotic allergy 











The responses to questions regarding the prevalence of penicillin allergy and mechanisms of cross-
reactivity are summarised in Table 3. There was no difference in understanding of penicillin and beta-
lactam cross-reactivity comparing those with < 10 and ≥ 10 years experience (Figure 3). In patients 
with a history of immediate penicillin hypersensitivity, only 15% (37/241) would consider 
ceftriaxone, 41% (101/241) meropenem and 63% (152/241) aztreonam safe to administer in this 
clinical scenario, despite low rates of cross-reactivity (Table 3). Twenty four percent (57/237) of 
respondents would administer benzylpenicillin in the setting of community acquired pneumonia, 67% 
(159/237) preferring ceftriaxone, in a patient with a childhood history of mild delayed 
hypersensitivity (i.e. maculopapular exanthema [MPE]) to penicillin. Seven percent (16/237) would 
employ moxifloxacin in this scenario. In the case of methicillin-sensitive Staphylococcus aureus 
bloodstream infection in a patient with a history of childhood MPE, a 1st generation cephalosporin was 
the treatment of choice (47%, 112/237), followed by flucloxacillin (26%, 62/237), flucloxacillin following 
desensitisation (11%, 26/237), clindamycin (7%, 6/237) and vancomycin (6%, 15/237) therapy.  
 
DISCUSSION: 
In the current era of increasing antimicrobial resistance, opportunities to improve antibiotic prescribing 
are essential. Attention has turned to antibiotic allergy de-labelling to enhance AMS programs14. 
Before de-labelling can be incorporated into AMS, assessments of current Australian and New 
Zealand antibiotic allergy service provisions and stakeholder knowledge are required to identify the 
barriers to implementing multi-disciplinary AAT services. We surveyed Australian and New Zealand 
clinicians and pharmacists to examine the current and future requirements of AAT programs and 
attitudes toward antibiotic allergy.  
Our survey highlights a demand for AAT amongst key stakeholders irrespective of clinical experience, 
contrasted with significant operational barriers. Whilst antibiotic allergies encountered by infectious 
diseases physicians are being increasingly found to impact on antibiotic selection, antibiotic 
appropriateness and antimicrobial resistance6, 8, 15, less than half infectious diseases specialists had 
AAT available, likely reflective of poor access.  When available, testing to a vast array of β-lactams, 
including the implicated antibiotic, was offered. There appears a desire to refer patients with a history 
of immediate hypersensitivity over delayed, potentially reflecting a perception of less robust options 
for the management and diagnosis for T-cell mediated reactions. This is interesting as antibiotics 
contribute almost 50% of severe cutaneous adverse reactions16, and both in vivo (skin testing) and ex 
vivo diagnostics are continually improving17-19. In addition clinical phenotyping and risk stratification is 
even more important for many serious delayed reactions to avoid future morbidity and mortality 
related to re-exposure to a suspect drug or one that is structurally related. Most respondents were 
optimistic that overall AAT could aid AMS and, if more easily accessible, would employ AAT in their 
AMS programs. 











We identified significant knowledge gaps among surveyed clinicians and pharmacists that did not 
correlate with years of clinical experience. Compounding either a true or perceived absence of AAT, is 
a potential misunderstanding of antibiotic allergy, previously noted in the US 20. Whilst historical 
estimates of IgE mediated cephalosporin and penicillin cross-reactivity were 15-25%, more 
contemporary studies suggest the true rate of cross-reactivity to be <2% and potentially lower for third 
and later generation cephalosporins 21-23. Recent studies suggest the rate of immediate carbapenem 
and penicillin allergy cross-reactivity to be also extremely low (<1%) 24, 25. This contrasts with our 
surveyed stakeholders, 78% of whom suggested a cephalosporin cross-reactivity rate > 2% and 58%, 
a meropenem cross-reactivity of > 1%. Furthermore, despite most childhood-onset MPE being 
secondary to viral exanthema or antibiotic/viral interaction 26, 27 rather than antibiotic exposure, 
clinicians and pharmacists were reluctant to administer a preferred penicillin therapy in these patients 
with community-acquired pneumonia and Staphylococcus aureus bloodstream infection. Despite the 
high negative predictive value of penicillin skin prick testing and oral challenge1, 35% of respondents 
were still unsure or unwilling to prescribe penicillin in the setting of a negative testing. Investment in 
updating undergraduate and continuing medical and pharmacy antibiotic allergy education would 
enhance clinical knowledge and potentially improve antibiotic utilization amongst key stakeholders28.  
 
Study limitations include the diversity of the surveyed population, including the fact that some 
responses were obtained from non-practicing clinicians. Notwithstanding this limitation, 85% of 
respondents were current prescribers of antibiotics and actively engaged in clinical care. An accurate 
estimate of overall response rates could not be obtained due to overlap across the studied 
membership bases. As with all studies employing voluntary survey participation, the potential for 
selection bias is recognised. It is possible respondents represented a biased sample of those with an 
interest in AAT. Nonetheless, this survey provides the first attempt at understanding current AAT 
practices and service provision in Australia and New Zealand  
 
Although models of antibiotic allergy care have been proposed,28-30 a standardised or multidisciplinary 
approach to AAT testing in Australia and New Zealand does not currently exist. We have 
demonstrated one of the preferred models to be a partnership between allergists, clinical 
immunologists, pharmacists and infectious diseases physicians. Similar multidisciplinary models in 
cancer patient AMS programs, engaging relevant clinicians, have lead to significant improvements in 
quality of care and mortality benefits31. Improved knowledge of antibiotic allergy and the role ATT will 
help promote allergy services as a safe and effective service.  
 
CONCLUSION: 











Despite a high antibiotic allergy label prevalence and demand for AAT services, current 
implementation barriers include lack of access to appropriate specialist healthcare providers to carry 
out AAT as well as cost of delivery.  A collaborative model of infectious diseases physicians, 
pharmacists and allergists/clinical immunologists would enable targeted AAT delivery to those that 
require it, improving antibiotic utilisation, choice and drug safety. Current knowledge gaps suggest 
that education of clinicians and pharmacists and engagement of allergy and infectious diseases 
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AAT – Antibiotic allergy testing 
AMS – Antimicrobial Stewardship 
ASCIA – Australasian Society of Clinical Immunology and Allergy 
ASID – Australasian Society of Infectious Diseases 
IDT – Intradermal testing 
RACP – Royal Australasian College of Physicians 
SHPA – Society of hospital pharmacists Australia 

















Table 1: Baseline demographics of survey respondents. 
Baseline demographics  
 
Total N = 277 
Medical training college 
   Royal Australasian College of Physicians    Royal Australasian College of Surgeons    Royal Australian College of General Practitioners    Royal College of Pathologists 
170 (61) 160 (58) 2 (1) 4 (1) 4 (1) 
Member of Society of Hospital Pharmacists 92 (33) 
Member of Australasian Society of Infectious 
Diseases 
101 (37) 
Member of Australasian Society of Clinical 
Immunology & Allergy 
81 (32) 








   <10 years  157 (57) 
Hospital Setting 




Currently involved in clinical practice that requires 
















Table 2: Antibiotic allergy phenotypes referred for testing 
Allergy phenotypes referred for testing, n (%) 




IgE SCAR MPE 
Infectious diseases physicians (n = 48) 32 (67) 7 (15) 17 (35) 6 (13) 
Pharmacists (n= 28) 22 (79) 5 (18) 7 (25) 4 (14) 
Allergists/Immunologists (n = 53) 47 (89) 1 (2) 17 (32) 3 (6) 
Other (n = 15)a 9 (60) 3 (20) 2 (7) 7 (47) 
Total (n = 144) 110 (76) 16 (11) 43 (30) 20 (14) 
a Includes general practitioners, general physicians, microbiologists 
Definitions: SCAR, severe cutaneous adverse reactions; MPE, maculopapular exanthema; SCAR, 
severe cutaneous adverse reactions, MPE, maculopapular exanthems. 
  











Table 3: Knowledge of Antibiotic Allergy Cross-Reactivity 





















The major cause of cross-reactivity 
between amoxicillin and cephalexin 
allergy is the beta-lactam ring 
False 
 
48 38 36 48 42 
What is the rate of immediate 3rd 
generation cephalosporin allergy in a 
patient with penicillin allergy? 
<1-2% 
 
6 18 48 35 21 
What is the rate of immediate 




46 31 50 28 40 
What is the rate of immediate 




79 46 63 41 61 
*Evidence based responses based upon references: 23, 24, 32 
a Includes general practitioners, general physicians, microbiologists 

























Legend: The availability of antibiotic allergy testing (y-axis, %) for various antibiotics (x-axis) is demonstrated. The percentage value is representative of the 



















































Availability of antibiotic allergy testing
Infectious Diseases Allergists/Immunologists Pharamacists Other Total




















































Absence of personal experience





























































< 10 years clinical experience> 10 years clinical experience
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